Merck KGaA (MRK.DE) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of DAX

Merck KGaA (MRK.DE) closed at EUR 141.90 on 2026-10-14, a change of +27.5 % over the past year, with a market capitalization of EUR 62.28B.

Merck KGaA recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Merck KGaA key figures

Previous close

EUR 141.90 (2026-10-14)

1-year change

+27.5 %

Market cap

EUR 62.28B

Enterprise value

EUR 71.41B

P/E ratio (trailing)

25.95

P/E ratio (forward)

16.04

EPS (trailing)

5.52

EPS (forward)

8.93

PEG ratio

2.29

Price to book

2.06

Revenue growth

3.4 %

Earnings growth

-24.7 %

Dividend per share (trailing)

2.20

Short ratio

n/a

Employees

62,136

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Merck KGaA

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Merck KGaA and compare it with other stocks.